denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: an independent educational grant from AstraZeneca Pharmaceuticals LP.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Leukemia, Adult, Diseases, CLL, Therapies, Adverse Events, Lymphoid Malignancies, Study Population, Clinically relevant
Hematology Disease Topics & Pathways:
Leukemia, Adult, Diseases, CLL, Therapies, Adverse Events, Lymphoid Malignancies, Study Population, Clinically relevant
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Jennifer Woyach, MD, The Ohio State University, Comprehensive Cancer Center
Disclosures:
Woyach: Verastem: Research Funding; Arqule: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Karyopharm: Research Funding; Morphosys: Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding.
Speakers:
John N. Allan, MD, Weill Cornell Medicine
and
Deborah M. Stephens, DO, University of Utah/Huntsman Cancer Institute
Disclosures:
Allan: Genentech: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; Ascentage Pharma Group: Consultancy, Honoraria; Cellectar: Consultancy, Honoraria; Celgene: Research Funding; TG Therapeutics: Research Funding; Abbvie: Consultancy, Honoraria, Speakers Bureau. Stephens: Arqule: Research Funding; Pharmacyclics: Consultancy; Verastem: Research Funding; Karyopharm: Consultancy, Research Funding; Innate: Consultancy; Gilead: Research Funding; Beigene: Consultancy; Juno: Research Funding; Acerta: Research Funding; MingSight: Research Funding; Janssen: Consultancy.
Join us for this interactive, case-based, symposium where you can test your knowledge and skills using BTK inhibitors for the treatment of patients with treatment-naïve and relapsed/refractory CLL. Using a tumor board approach, the panel will discuss real-world examples and will put the trial data for BTK inhibitors into clinical context. The audience will vote on treatment choices for patients and how they would manage treatment-related side effects. The panel will discuss best practices for recognizing and mitigating side effects of BTK inhibitors. The symposium will also include future directions for BTK inhibitors, such as novel agents and investigational combinations.
See more of: Satellite Symposia